2022 Annual Report and Accounts
LLOYDS BANK PLC ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2022
LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- In accordance with Listing Rule 9.6.1, Lloyds Bank plc announces that the following document will be submitted today to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
A copy of the document is also available through the 'Investors' section of our website www.lloydsbankinggroup.com
This announcement is made in accordance with DTR 6.3.5R(1A).
|For further information:|
|Douglas Radcliffe||+44 (0)20 7356 1571|
|Group Investor Relations Director|
|Matt Smith||+44 (0)20 7356 3522|
|Head of Media Relations|
FORWARD LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of Section 21E of the US Securities Exchange Act of 1934, as amended, and section 27A of the US Securities Act of 1933, as amended, with respect to the business, strategy, plans and/or results of Lloyds Bank plc together with its subsidiaries (the Lloyds Bank Group) and its current goals and expectations. Statements that are not historical or current facts, including statements about the Lloyds Bank Group's or its directors' and/or management's beliefs and expectations, are forward looking statements. Words such as, without limitation, 'believes', 'achieves', 'anticipates', 'estimates', 'expects', 'targets', 'should', 'intends', 'aims', 'projects', 'plans', 'potential', 'will', 'would', 'could', 'considered', 'likely', 'may', 'seek', 'estimate', 'probability', 'goal', 'objective', 'deliver', 'endeavour', 'prospects', 'optimistic' and similar expressions or variations on these expressions are intended to identify forward looking statements. These statements concern or may affect future matters, including but not limited to: projections or expectations of the Lloyds Bank Group's future financial position, including profit attributable to shareholders, provisions, economic profit, dividends, capital structure, portfolios, net interest margin, capital ratios, liquidity, risk-weighted assets (RWAs), expenditures or any other financial items or ratios; litigation, regulatory and governmental investigations; the Lloyds Bank Group's future financial performance; the level and extent of future impairments and write-downs; the Lloyds Bank Group's ESG targets and/or commitments; statements of plans, objectives or goals of the Lloyds Bank Group or its management and other statements that are not historical fact; expectations about the impact of COVID-19; and statements of assumptions underlying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon circumstances that will or may occur in the future. Factors that could cause actual business, strategy, plans and/or results (including but not limited to the payment of dividends) to differ materially from forward looking statements include, but are not limited to: general economic and business conditions in the UK and internationally; political instability including as a result of any UK general election and any further possible referendum on Scottish independence; acts of hostility or terrorism and responses to those acts, or other such events; geopolitical unpredictability; the war between Russia and Ukraine; the tensions between China and Taiwan; market related risks, trends and developments; exposure to counterparty risk; instability in the global financial markets, including within the Eurozone, and as a result of the exit by the UK from the European Union (EU) and the effects of the EU-UK Trade and Cooperation Agreement; the ability to access sufficient sources of capital, liquidity and funding when required; changes to the Lloyds Bank Group's or Lloyds Banking Group plc's credit ratings; fluctuations in interest rates, inflation, exchange rates, stock markets and currencies; volatility in credit markets; volatility in the price of the Lloyds Bank Group's securities; tightening of monetary policy in jurisdictions in which the Lloyds Bank Group operates; natural pandemic (including but not limited to the COVID-19 pandemic) and other disasters; risks concerning borrower and counterparty credit quality; longevity risks affecting defined benefit pension schemes; risks related to the uncertainty surrounding the integrity and continued existence of reference rates; changes in laws, regulations, practices and accounting standards or taxation; changes to regulatory capital or liquidity requirements and similar contingencies; the policies and actions of governmental or regulatory authorities or courts together with any resulting impact on the future structure of the Lloyds Bank Group; risks associated with the Lloyds Bank Group's compliance with a wide range of laws and regulations; assessment related to resolution planning requirements; risks related to regulatory actions which may be taken in the event of a bank or Lloyds Bank Group or Lloyds Banking Group failure; exposure to legal, regulatory or competition proceedings, investigations or complaints; failure to comply with anti-money laundering, counter terrorist financing, anti-bribery and sanctions regulations; failure to prevent or detect any illegal or improper activities; operational risks; conduct risk; technological changes and risks to the security of IT and operational infrastructure, systems, data and information resulting from increased threat of cyber and other attacks; technological failure; inadequate or failed internal or external processes or systems; risks relating to ESG matters, such as climate change (and achieving climate change ambitions), including the Lloyds Bank Group's or the Lloyds Banking Group's ability along with the government and other stakeholders to measure, manage and mitigate the impacts of climate change effectively, and human rights issues; the impact of competitive conditions; failure to attract, retain and develop high calibre talent; the ability to achieve strategic objectives; the ability to derive cost savings and other benefits including, but without limitation, as a result of any acquisitions, disposals and other strategic transactions; inability to capture accurately the expected value from acquisitions; and assumptions and estimates that form the basis of the Lloyds Bank Group's financial statements. A number of these influences and factors are beyond the Lloyds Bank Group's control. Please refer to the latest Annual Report on Form 20-F filed by Lloyds Bank plc with the US Securities and Exchange Commission (the SEC), which is available on the SEC's website at www.sec.gov, for a discussion of certain factors and risks. Lloyds Bank plc may also make or disclose written and/or oral forward-looking statements in other written materials and in oral statements made by the directors, officers or employees of Lloyds Bank plc to third parties, including financial analysts. Except as required by any applicable law or regulation, the forward-looking statements contained in this document are made as of today's date, and the Lloyds Bank Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained in this document whether as a result of new information, future events or otherwise. The information, statements and opinions contained in this document do not constitute a public offer under any applicable law or an offer to sell any securities or financial instruments or any advice or recommendation with respect to such securities or financial instruments.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that
Inventiva reports its 2022 full-year results29.3.2023 22:00:00 CEST | Press release
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva received the first tranche of €25 million under its credit facility with the European Investment Bank (EIB) Screening of the first patients in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D Secured a new patent expanding the IP protection of lanifibranor in the U.S. In January 2023, Inventiva announced changes to NATiV3, a Phase III trial with lanifibranor in patients with NASH, that are expected to be beneficial to the clinical program Daix (F
Nova Klúbburinn hf.: Niðurstöður aðalfundar þann 29. mars 202329.3.2023 21:54:28 CEST | Press release
Aðalfundur Nova Klúbbsins hf. var haldinn í dag, miðvikudaginn, 29. mars 2023. Þetta var fyrsti aðalfundur í skráðu félagi sem eingöngu var stýrt af konum en Hrund Rudolfsdóttir flutti skýrslu stjórnar, Margrét Tryggvadóttir skemmtana- & forstjóri fór yfir árið, Svanhildur Magnúsdóttir var fundarstjóri og ritari fundar var Ásta Guðjónsdóttir. Í stjórn félagsins voru kjörnir eftirfarandi einstaklingar: Hrund Rudolfsdóttir Jón Óttar Birgisson Jóhannes Þorsteinsson Magnús Árnason Sigríður Olgeirsdóttir Jóhannes, Sigríður og Magnús koma inn í stjórnina í stað Hugh Short, Kevin Payne og Tinu Pidgeon. Stjórn hefur skipt með sér verkum og var Sigríður Olgeirsdóttir kjörinn formaður stjórnar. Jóhannes Þorsteinsson starfar í dag sem yfirmaður fjárstýringar T-Mobile í Bandaríkjunum, þar sem hann ber ábyrgð á allri fjármögnun fyrirtækisins. T-Mobile er leiðandi fyrirtæki á fjarskiptamarkaði í Ameríku. Sigríður Olgeirsdóttir er reyndur stjórnandi í hugbúnaðar- og hátæknigeiranum. Magnús er sjálfst
Orkuveita Reykjavíkur – Green Bond Offering Results29.3.2023 20:44:54 CEST | Press release
Today, March 30th, Orkuveita Reykjavíkur (OR; Reykjavik Energy) concluded a closed green bond offering in series OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued with a nominal value of ISK 12,617 million in the category. The series attracted bids totalling ISK 2,160 million nominal value at yields between 3.17% and 3.35%. OR accepted bids amounting to ISK 1,960 million at a yield of 3.24%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds have been issued with a nominal value of ISK 22,601 million in the category. The series attracted bids totalling ISK 820 million nominal value at yields between 2.99% and 3.15%. OR accepted bids amounting to ISK 620 million at a yield of 3.04%. Fossar Investment Bank oversees the issuance and sale of the b